Bausch targets India-based firm over IBS drug generic

Pharma giant claims infringement of two patents | Hyderabad-based rival’s letter offering details of proposed generic allegedly lacked certain required details.

Life Sciences Intellectual Property Review (LSIPR)  tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.  Methoxydienone

Bausch targets India-based firm over IBS drug generic

To continue reading this article and to access  4,500+ articles,  our digital magazines and special reports  published for LSIPR subscribers only then  you will need a  subscription.  If you are already subscribed please login.

Allen & Overy Arnold & Siedsma Birch, Stewart, Kolasch & Birch LLP (BSKB) Carpmaels & Ransford Cooley European Patent Office Finnegan LLP GH Research Gowling WLG George Washington Law School HGF Limited IQVIA Kirkland & Ellis International LLP Marks & Clerk Mintz Levin NiKang Therapeutics Inc. Powell Gilbert LLP Procopio, Cory, Hargreaves & Savitch LLP Taylor Wessing The United States Patent and Trademark Office (USPTO) Valea AB World Intellectual Property Office 

For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at

If you have any technical issues please email tech support .

generic, Bausch, patents, Trulance, Orange Book, USPTO, ANDA, Salix Pharmaceuticals, MSN, Trulance, plecanatide,

Bausch Ireland fends off challenge to its cancer patent 12-09-2023

Bausch targets Israeli firm in skin treatment dispute 22-06-2023

Bausch Health resolves IBS patent litigation 07-05-2020

Bausch Health resolves IP litigation with Teva 02-08-2019

Newton Media Ltd Kingfisher House 21-23 Elmfield Road Bromley BR1 1LT United Kingdom

Bausch targets India-based firm over IBS drug generic

Oxytocin Acetate Receive the latest news from LSIPR